Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as one of the 11 best-performing stocks over the past 12 months [1] Group 1: Strategic Developments - Terns Pharmaceuticals has amended its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd., converting a non-exclusive, royalty-free license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701, excluding the Hansoh Territory [2] - The company will pay a one-time upfront license fee of $1.0 million and tiered royalties of 0.75%-1.25% on annual net sales of TERN-701 products, with potential reductions applicable [3] Group 2: Analyst Sentiment - Citizens has raised its price target for Terns Pharmaceuticals from $35 to $57, maintaining an 'Outperform' rating, reflecting positive sentiment based on the interim Phase 1 CARDINAL ASH update showcasing TERN-701's strong profile and response rates [4] Group 3: Company Focus - Terns Pharmaceuticals specializes in developing small-molecule and combination therapies targeting NASH, oncology, and chronic liver disease, with clinical-stage programs focused on FXR, VAP-1, THR-β, and GLP-1 [5]